Chief Investment Office WM 19 September 2014

Similar documents
UBS Compensation Survey 2017

UK economy. BREXIT: into the final furlong. Dean Turner, CFA Economist CIO WM UK UBS Wealth Management. Source: istock

Annual UBS investment Lecture. Welcome

CIO WM Research. Swiss Chartset Last update: 8 January 2014

UBS House View. Treasurers Forum the year ahead. November Chief Investment Office WM. Published 3 November 2015

UBS CIO Houseview and Year ahead

Dr. Andreas Höfert, UBS Chief Economist. Swiss American Chamber of Commerce Zurich, October 30, 2009

Chief economist's comment

Swiss Chartset. Last update: 07 September 2018

Chief economist's comment

Chief economist's comment

Sustainable investing

Swiss real estate market

Chief economist's comment

Becton Dickinson & Co

CIO Monthly Letter. Teaming up to perform

Pricing Guidelines for Listed Products and OTC Derivatives Clearing Services offered by UBS EMIR Articles 38(1) and 39(7)

US equities. Will the Amazon, JP Morgan and Berkshire venture change healthcare?

Chief economist's comment

Teva Pharmaceuticals

Chinese equities. A-shares join MSCI's index universe

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 10February2017. PositiveXareltoStudyAddsTailwindtoPharma Estimates

Closed-end fund update

Baxter International Inc.

Bristol-Myers Squibb

Future of food demand

UBS CIO Monthly Letter

1. Introduction. 2. Client Profitability

Stryker Corporation. UnitedStatesofAmerica/Equipment&Services 26February2016. AddingScaletoMedical,EnhancingGrowth

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 15December2016. SlightlyBetterThanExpected2017Guidance

Global economy. Italy and the euro are investors lost in translation?

Smith & Nephew. UnitedKingdom/HealthcareEquipment& Supplies 9February2017. Q4&H2largelyinline.GuidanceOK.

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 15February2017. Q1U.S.PharmaTrendsOfftoaStrongStart

UBS HouseView. Bubble thoughts. Digest. US Edition CIO Wealth Management Research. December 2013

Fresenius Medical Care

Bristol-Myers Squibb

Fresenius SE & Co KGaA

Teva Pharmaceuticals

Pfizer Inc. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 31January2017. In-Line4Q;GuidanceWeakerduetoFX

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 23November2015. UpdatingEstimatesforDaraandPharmaTrends

Sanofi. France/Pharmaceuticals 16February2017. ModelupdatepostFY2016results(PriceTargetto 82from 78,Neutralratingretained)

Allergan Plc. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 26April2016. AllerganShouldBeaCoreHoldingAgain

Chief economist's comment

Portfolio principles. Loss-harvesting to save taxes 4 October begin on page 4.

Boston Scientific Corp.

Chief economist's comment

Bristol-Myers Squibb

S&P Dow Jones Disclaimer

Zimmer Biomet Holdings, Inc.

Merck & Co. UnitedStatesofAmerica/Pharmaceuticals 15December2015. FinallyGoodNewsForBridion

Smith & Nephew. UnitedKingdom/HealthcareEquipment& Supplies 5May2016. China&MiddleEastimpactgreaterthan thought

(Luxembourg) 6Y EUR Global Performance Notes 11/17. Description of the coupon fixing mechanism. Promotional document

Teva Pharmaceuticals

Pfizer Inc. UnitedStatesofAmerica/Pharmaceuticals 27October2015. MuchBetterThanExpected

Direct Execution UBS ATS. Rules of Engagement Addendum for Conditional Indications

Pfizer Inc. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 2February2016. AnIn-lineQuarter;2016GuidanceOffSome

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 18January2017. AddingAnotherStrategicAsset

Merck KGaA. Germany/Pharmaceuticals 7December2015. Merckdropsevofosfamideinsofttissuesarcoma &pancreaticcancerafterphiiifailures

Equity Markets PRIVATE PLACEMENT ONLY

Celgene Corporation. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 8March2016. AbraxaneANDAIsGoingtoTakeaWhile

Merck & Co. UnitedStatesofAmerica/Pharmaceuticals 25October2016. TimetoWatchKeytrudaRamp

Medtronic, Inc. UnitedStatesofAmerica/Equipment&Services 18May2016. AddingRobotstoSpine ExtendingtheCapital- ConsumableStrategy

Flash Note Currencies: EUR/USD

Sanofi. France/Pharmaceuticals 13December2016. Lowpharmapricingpoweroffsetbylow expectations.maintainneutralrating

Flash Note Switzerland: Q2 GDP growth

Deutsche Invest I Euro High Yield Corporates

Novartis. Switzerland/Pharmaceuticals 22March2017. AnotherCV-shapedstumblingblockinpursuitof pharmatop-linegrowth

2Y Lufthansa Fix Kupon Express Anleihe

Novo Nordisk. Denmark/Pharmaceuticals 19January2017. Amicrosegmentationofdiabetesdynamics

Charting the Course. Can MXAPJ Sustain Jan Rally? Rotational Opportunities Best; Asia Technicals Strategy

Pfizer Inc. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 2February2016. UnderlyingFundamentalsSlowlyImproving

5Y EUR ING Capped Floored Floater Note

Merck & Co. UnitedStatesofAmerica/Pharmaceuticals 5May2016. NoMajorSurprises;EyeNowOnASCO

USD ING Memory Phoenix Autocallable ING Bank NV (NL) USD 5,000,000 Express Certificates linked to SX5E due

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 26April2016. NextUp,InterimAbemaciclibData

FOR 2018 GLOBAL MARKET OUTLOOK PRESS BRIEFING. PROVIDED TO DESIGNATED MEMBERS OF THE PRESS ONLY, NOT FOR FURTHER DISTRIBUTION.

5.60% p.a. CHF Callable Kick-In GOAL Linked to worst of Carrefour / Danone / Nestlé Issued by UBS AG, London Branch

Bristol-Myers Squibb

Eisai. Japan/Pharmaceuticals 23November2016. Solanezumabfails;negative

UBS Economics Day The Australian Budget

Pfizer Inc. UnitedStatesofAmerica/Pharmaceuticals 27October2015. PfizerRemainsaNiceRiskReward

Bristol-Myers Squibb

DWS Euro-Bonds (Long)

Cash Alternatives. Liquidity Solutions. 1. Introduction

Global economy. Is a trade war likely? The trade debate in May

Global Research February 2017

Flash Economics. The end of quantitative easing in the euro zone: Will banks step in for the ECB to buy government bonds?

Long-duration: Volatility in isolation, safety in context Blog

Open End Turbo Call Warrant Linked to Richemont Issued by UBS AG, Zurich

Flash Economics. What adjustments are possible when unemployment returns to the structural unemployment level?

Investing in Mexico. Monthly strategy update

Transcription:

Chief Investment Office WM 19 September 2014 Subordinated bonds Volatility to persist Corporate hybrids have recouped their losses since the summer sell-off. Investment grade rated instruments returned 7.9% year to date, while high yield rated instruments posted returns slighly above 8%. The prevailing ultra-low yield environment, the ECB's more aggressive stance and speculation about further monetary policy measures should ultimately support the corporate hybrid segment. As most instruments in our coverage universe also continue to compensate relatively well for hybrid-specific risks, we continue to see value. However, the slowing growth momentum in Europe, geopolitical risks and increasing rate uncertainty will amongst other things likely keep volatility elevated. Although we expect the asset class to remain more defensive than stocks or lower quality high yield bonds during a sell-off period, we highlight that corporate hybrids should only be held in diversified portfolios. We have screened our coverage universe for relative value opportunities and provide updated trading recommendations in this note. Rochus Baumgartner, FRM, analyst, UBS AG rochus.baumgartner@ubs.com Rafael Bucher, analyst, UBS AG rafael.bucher@ubs.com Thomas Rauh, analyst, UBS AG thomas.rauh@ubs.com Source: UBS The corporate hybrid asset class has staged a comeback since the summer sell-off. The BoA Global Hybrid NF Corporate Index, which consists mainly of investment grade-rated European corporate hybrid bonds, has posted a year to date total return of 7.5%, whereas the BoA Global Hybrid NF Corporate HY Index (consisting mainly of HY rated European hybrids) has returned more than 8%. Although Telefonica's EUR 7.625 Perp has been the best-performing instrument in our EUR coverage universe, higher beta hybrids have not outperformed in general. As is depicted in Fig. 3, bond performance trends this year can largely be explained by duration effects and the strong performance of EDF EUR 5.375 perp, Dong EUR 6.25 3013 and VW EUR 5.125 perp mainly reflects the falling rates in Europe. Fig.1: Year to date total return comparison (EUR denominated bonds in %) Technical tailwinds persist As paradoxical as this may have sounded some years ago, deteriorating economic data prints have in the recent past usually been good news for corporate bonds, as expectations for additional or longer stimulus measures usually lead to tighter spreads. Although this correlation will break down at some stage (certainly at the lower end of the rating spectrum when low growth could eventually also lead to higher default rates) and although its This report has been prepared by UBS AG. Please see important disclaimers and disclosures that begin on page 10. Past performance is no indication of future performance. The market prices provided are closing prices on the respective principal stock exchange. This applies to all performance charts and tables in this publication.

ultimate impact is debated, we still see the more aggressive stance the European Central Bank (ECB) has recently adopted as supporting the wider European corporate bond segment: The purchase of assetbacked securities (ABS) or covered bonds, and the lower rates, should in our view continue to push investors into spread products, and the demand for higher yielding credit assets should therefore remain supported. Speculation about even further measures and a full quantitative easing program (we currently assign a 40% probability to a scenario in which the ECB would buy sovereign bonds) could thereby tighten spreads further in the coming months, of which also the corporate hybrid segment should benefit - even though it is unlikely to be targeted directly by ECB purchases. As long as the market needn't digest a further material uptick in new issue supply (a high proportion of the record volume brought to the market in this year was M&A related, and forecasting future issuance is rather tricky), we hence continue to see a supportive technical backdrop. Most instruments still compensate well for structural risks From a fundamental perspective, we also see value in corporate hybrids and, at current spread levels, still regard investors as relatively well compensated for assuming the structural risks associated with them. The brown shaded part in Fig. 5 reflects the spread an instrument offers over the interpolated senior curve and a necessary add-on to reflect the zero-recovery prospects of these bonds in a default scenario. This additional premium should essentially be viewed as compensation for the remaining structural risks, including a potential coupon deferral, an instrument's illiquidity or a possible "101 call." Fig. 2: Total return comparison IG and HY hybrids versus broad IG corporate and HY indices (EUR denominated) 110.0% 108.0% 106.0% 104.0% 102.0% 100.0% 98.0% 12/2013 02/2014 04/2014 06/2014 08/2014 Corp. Hybrids (IG) EUR Corporates (IG) Source: Bank of America, as of 19 September 2014 Corp. Hybrids (HY) EUR HY Fig. 3: YTD Total returns by duration YTD total return (y-axis) versus duration (x-axis) of EUR denominated instruments As we have highlighted before, we consider a premium of 50-100bps to be adequate for the older style instruments, whose call is coming up next year (i.e. the bonds of Bayer, Siemens, Henkel and Vattenfall), given the issuers' comparatively solid credit profiles (and the low probability of a mandatory deferral), the fact that special calls would only be possible at make-whole prices (or not at all) and our view that the instruments could likely be replaced at a lower spread than the stepped-up margin, which would become applicable were the instruments to remain outstanding. The compensation is currently materially higher for most of the more recently issued bonds (see Fig. 5). However, here too we currently believe that extension risks are mostly limited since the equity credit that issuers receive for these instruments normally expires after the first call date (at least with S&P), which we see as a more or less strong call incentive. Coupon deferral risk would increase, however, should an issuer's credit profile deteriorate sharply. But in this case we could still draw some comfort from the fact that the coupons for the most part could only be deferred on a cumulative basis (meaning that issuers would have to pay deferred coupons at a later stage), which in our view should reduce the incentive of issuers resorting to this measure. UBS CIO WM 19 September 2014 2

However, a less predictable but still relevant risk on these newer structures are special calls. These clauses, prevalent in most hybrids, allow issuers to redeem their instruments early (usually at a price of 101) when a material change in the accounting or tax treatment of the bonds occurs or if a methodical change by a rating agency reduces the equity credit on a particular instrument (see "Supported by ultra-low yield environment", published in April 2014 for a more detailed explanation). As we have highlighted previously, we generally do not place bonds with high cash prices on our recommendation lists due to this risk. In this report, we are also adopting a more cautious stance toward RWE, whose bonds may lose their equity credit (and hence become callable) with S&P, should it decide to repay rather than replace its EUR 4.625 perpetual bond next year (see below). Fig. 4: Supply Face value of outstanding bonds (EUR bn) 60 50 40 30 20 10 0 2010 2011 2012 2013 2014 IG rated hybrids Source: Bank of America, as of 17 September 2014 HY rated hybrids Fig. 5: Compensation for hybrid specific risks (bps) Bottom part of each column reflects an issuer's senior spread level, the mid part represents the compensation for subordination while the top part reflects the premium for other hybrid specific risks (incl. deferral, extension or liquidity risks) UBS CIO WM 19 September 2014 3

Volatility to increase? Even though we foresee a supportive technical backdrop and believe that most instruments continue to compensate well for structural risks, we do not see smooth sailing ahead. Apart from ongoing geopolitical tensions we also see the loss in economic momentum in the Eurozone as key volatility driver for the asset class over the midterm. Should growth not pick up, imbalances between company fundamentals and spreads could grow further, which could expose hybrid valuations to a correction at some stage. Another risk stems from higher US rates or higher rate volatility in general: To what extent the exit of foreign or non-traditional credit investors could be facilitated is not clear but the potential spread impact of a larger exodus could be significant - given the relative illiquidity of corporate bond markets. Although we generally expect the asset class to remain more defensive during a sell-off period than for example stocks or weaker quality high yield bonds, we therefore continue to highlight that hybrid instruments should only be held in diversified portfolios by investors able and willing to stomach the volatility. Fig. 6: Relative value comparison GBP Yield to call in % by first call date UBS CIO WM 19 September 2014 4

Fig. 7: Relative value comparison EUR Yield to call in % by first call date UBS CIO WM 19 September 2014 5

Recommendations We use a multifactor regression model as a first step in the process of determining the relative attractiveness of the spread-to-call of the "newer style" corporate hybrid bonds in our coverage universe. Our current model includes a rating variable, an instrument's duration (which is also a proxy for the time to first call), a variable reflecting our view on an issuer's rating trend and a dummy variable that identifies issuers from the European periphery. All explanatory variables and the calculated intercept in our model have p-values of 5% or below (and are hence statistically relevant), and the coefficient of determination of our model is currently just below 80%. However, even though our regression can explain a high proportion of the spread variation within our hybrid coverage universe, various qualitative factors are of course not captured. We therefore use our model only as a first-cut analysis and overlay regression results with our general credit and valuation views on a particular issuer. We additionally also give consideration to the structural aspects otherwise not captured. Fig. 8: Valuation gap (bars) versus our view on the issuer's credit profile A blue colour shade indicates that our credit analysts do not currently expect a downgrade of the issuer's lowest agency rating over a 12 month horizon. A brown column shade indicates the possibility of a one notch downgrade whereas a green shade highlights the possibility of upgrades. UBS CIO WM 19 September 2014 6

With this report, we change our recommendation on RWE hybrids with high cash prices to expensive. While the issuer also remains under fundamental pressure, this predominantly reflects the risk of a possible 101 call, should RWE decide to repay (rather than replace) its EUR 4.625 perpetual in 2015 as the issuer has reportedly been considering. This would be in violation of S&P's recently reiterated methodologies in which the agency puts a lot of emphasis on the permanence of capital securities. The cash repayment could therefore cause the agency to lower the equity credit on the issuer's other hybrid instruments, which in turn would make them callable at 101. Fig. 9: Recent spread performance versus model spread Valuation gap (bps) to model spread (X-axis) versus 90 day spread Z-Score(Y-axis) UBS CIO WM 19 September 2014 7

Fig. 10: Coverage list GBP ISIN Issuer Maturity Next call Coupon Ratings Ind. yield (%) Current After next call MDY / S&P to call to mat. Ask price Piece Valuation Notes XS0259607777 LINDE FINANCE BV 14.07.2066 14.07.2016 8.125 3M +412.5bps Baa1 / A- 2.0 4.5 110.8 1 / 1 fair XS0266840486 SIEMENS FINANCIERINGSMAT 14.09.2066 14.09.2016 6.125 3M +225bps A2 / BBB+ 2.4 2.8 107.0 1 / 1 fair mandatory deferral triggers XS0267167566 GENERAL ELEC CAP CORP 15.09.2066 15.09.2016 5.500 3M +161.5bps A2 / AA- 1.8 2.2 107.1 50 / 1 fair XS0491212535 GE CAPITAL TRUST V 15.09.2066 15.09.2016 5.500 3M +161.5bps A2 / AA- 3.1 2.3 104.5 50 / 1 fair potential liquidity issues XS0319640834 GENERAL ELEC CAP CORP 15.09.2067 15.09.2017 6.500 3M +200bps A2 / AA- 2.9 2.6 110.3 50 / 1 fair XS0491211990 GE CAPITAL TRUST III 15.09.2067 15.09.2017 6.500 3M +200bps A2 / AA- 3.8 2.7 107.7 50 / 1 fair potential liquidity issues FR0011391838 VEOLIA ENVIRONNEMENT SA Perpetual 16.04.2018 4.850 5Y +362.9bps Baa3 / BB+ 4.7 5.4 100.6 100 / 100 attr active FR0011531722 GDF SUEZ Perpetual 10.01.2019 4.625 5Y + 330.8bps A3 / BBB+ 3.5 5.0 104.3 100 / 100 expensive XS0652913988 RWE AG Perpetual 20.03.2019 7.000 5Y +510bps Baa3 / BBB- 4.7 6.5 108.9 100 / 100 expensive XS0903872603 KONINKLIJKE KPN NV 14.03.2073 14.03.2020 6.875 5Y +550.5bps Ba2 / BB 5.8 7.0 104.9 100 / 1 attr active XS0954674825 ENEL SPA 10.09.2075 10.09.2020 7.750 5Y + 566.2bps Ba1 / BB+ 5.5 7.0 110.9 100 / 1 fair XS0997326441 TELEFONICA EUROPE BV Perpetual 26.11.2020 6.750 5Y + 445.8bps Ba1 / BB+ 5.6 6.2 105.6 100 / 100 attractive XS1014987355 ENEL SPA 15.09.2076 15.09.2021 6.625 5Y + 408.9bps Ba1 / BB+ 5.6 6.0 106.0 100 / 1 expensive XS1028597315 ORANGE SA Perp 07.02.2022 5.875 5Y + 335.4bps Baa3 / BBB- 5.3 5.4 103.1 100 / 1 attractive callable at 101 if issuer downgraded by Moody's potential withholding tax issues potential withholding tax issues XS0903532090 NGG FINANCE PLC 18.06.2073 18.06.2025 5.625 12Y +348bps Baa3 / BBB 4.9 5.6 105.7 100 / 1 expensive FR0011401728 ELECTRICITE DE FRANCE SA Perpetual 29.01.2026 6.000 13Y +395.8bps A3 / BBB+ 5.1 5.8 107.6 100 / 100 attractive FR0011700293 ELECTRICITE DE FRANCE SA Perpetual 22.01.2029 5.875 15Y + 304.6 A3 / BBB+ 5.3 5.4 105.5 100 / 100 fair Fig. 11: Coverage list USD / CHF ISIN Issuer Maturity Next call USD Coupon Ratings Ind. yield (%) Current After next call MDY / S&P to call to mat. Ask price Piece Valuation Notes XS0767140022 RWE AG 12.10.2072 12.10.2017 7.000 5Y$+575.4bps Baa3 / BBB- 3.7 7.0 109.5 2 / 2 expensive US36962G3M40 GENERAL ELEC CAP CORP 15.11.2067 15.11.2017 6.375 3M$+228.9bps A2 / AA- 2.9 2.6 110.3 5 / 1 fair US36830GAA22 GE CAPITAL TRUST I 15.11.2067 15.11.2017 6.375 3M$+228.9bps A2 / AA- 3.0 2.6 110.2 5 / 1 fair USF2893TAF33 ELECTRICITE DE FRANCE SA Perpetual 29.01.2023 5.250 10Y$+370.9bps A3 / BBB+ 4.8 5.7 103.1 100 / 1 fair USN4297BBC74 KONINKLIJKE KPN NV 28.03.2073 28.03.2023 7.000 10Y$+521bps Ba2 / BB 6.1 7.2 105.7 200 / 1 attr active USF2893TAM83 ELECTRICITE DE FRANCE SA Perpetual 22.01.2024 5.625 10Y$ + 304.1bps A3 / BBB+ 4.9 5.4 105.4 100 / 1 fair callable at 101 if issuer downgraded by Moody's CHF CH0136594352 RWE AG 04.04.2072 04.04.2017 5.250 5YCHF+438.9bps Baa3 / BBB- 3.0 5.0 105.3 5 / 5 expensive CH0185843049 RWE AG 26.07.2072 26.07.2017 5.000 5YCHF+ 465.7bps Baa3 / BBB- 2.8 0.6 105.9 5 / 5 expensive CH0212184037 ALPIQ HOLDING AG Perpetual 15.11.2018 5.000 5YCHF + 457.2bps N.A. / N.A. 5.2 5.1 99.4 5 / 5 fair non cumul. after 3 years UBS CIO WM 19 September 2014 8

Fig. 12: Coverage list EUR ISIN Issuer Maturity Next call Coupon Ratings Ind. yield (%) Current After next call MDY / S&P to call to mat. Ask price Piece Valuation Notes XS0223129445 VATTENFALL AB Perpetual 29.06.2015 5.250 3M +295bps Baa3 / BBB- 1.0 3.0 103.2 1 / 1 fair mandatory deferral triggers XS0225369403 BAYER AG 29.07.2105 29.07.2015 5.000 3M +280bps Baa3 / BBB- 1.3 2.9 103.1 1 / 1 fair mandatory deferral triggers XS0542298012 RWE AG Perpetual 28.09.2015 4.625 5Y + 265bps Baa3 / BBB- 1.9 3.1 102.7 1 / 1 fair XS0234434222 HENKEL AG & CO KGAA 25.11.2104 25.11.2015 5.375 3M +285bps Baa1 / BBB 1.2 2.9 104.8 1 / 1 fair mandatory deferral triggers XS0259604329 LINDE FINANCE BV 14.07.2066 14.07.2016 7.375 3M +412.5bps Baa1 / A- 1.0 4.0 111.3 1 / 1 fair XS0266838746 SIEMENS FINANCIERINGSMAT 14.09.2066 14.09.2016 5.250 3M +225bps A2 / BBB+ 0.9 2.3 108.5 1 / 1 fair mandatory deferral triggers XS0267166246 GENERAL ELEC CAP CORP 15.09.2066 15.09.2016 4.625 3M +160bps A2 / AA- 2.0 1.7 105.1 50 / 1 fair XS0491212451 GE CAPITAL TRUST IV 15.09.2066 15.09.2016 4.625 3M +160bps A2 / AA- 1.9 1.7 105.2 50 / 1 fair XS0674277933 ENBW 02.04.2072 02.04.2017 7.375 5Y + 540.1bps Baa2 / BBB- 2.3 5.6 112.2 1 / 1 fair XS0319639232 GENERAL ELEC CAP CORP 15.09.2067 15.09.2017 5.500 3M +200bps A2 / AA- 2.2 2.1 109.4 50 / 1 fair XS0491211644 GE CAPITAL TRUST II 15.09.2067 15.09.2017 5.500 3M +200bps A2 / AA- 2.3 2.1 109.2 50 / 1 fair XS0877720986 TELEKOM AUSTRIA AG Perpetual 01.02.2018 5.625 5Y +485.9bps Ba1 / BB+ 3.0 4.9 108.2 1 / 1 fair XS0808632763 IBERDROLA INTL BV Perpetual 27.02.2018 5.750 5Y +481bps Baa3 / BB+ 3.0 4.9 108.8 100 / 100 expensive FR0011391820 VEOLIA ENVIRONNEMENT SA Perpetual 16.04.2018 4.450 5Y +360.3bps Baa3 / BB+ 3.4 4.0 103.5 100 / 100 attr active XS0943371194 DONG ENERGY A/S 08.07.3013 08.07.2018 4.875 5Y + 380bps Baa3 / BB+ 2.8 4.1 107.4 1 / 1 fair FR0011531714 GDF SUEZ Perpetual 10.07.2018 3.875 5Y + 306bps A3 / BBB+ 2.3 3.4 105.7 100 / 100 fair XS0968913268 VOLKSWAGEN INTL FIN NV Perpetual 04.09.2018 3.875 5Y + 270bps Baa2 / BBB 2.3 3.1 106.0 1 / 1 fair XS0903872355 KONINKLIJKE KPN NV Perpetual 14.09.2018 6.125 5Y +520.2bps Ba2 / BB 4.1 5.3 107.5 100 / 1 attr active callable at 101 if issuer downgraded by Moody's XS0972570351 TELEFONICA EUROPE BV Perpetual 18.09.2018 6.500 5Y + 503.8bps Ba1 / BB+ 3.6 5.1 110.7 100 / 100 fair XS0954675129 ENEL SPA 10.01.2074 10.01.2019 6.500 5Y + 524.2bps Ba1 / BB+ 3.6 5.3 111.3 100 / 1 fair potential withholding tax issues FR0011606169 CASINO GUICHARD PERRACHO Perpetual 31.01.2019 4.870 5Y + 381.9bps N.A. / BB 3.6 4.2 104.8 100 / 100 attr active FR0011942226 GDF SUEZ Perpetual 02.06.2019 3.000 5Y + 233bps A3 / BBB+ 2.5 2.8 102.2 100 / 100 fair XS1014997073 ENEL SPA 15.01.2075 15.01.2020 5.000 5Y + 364.8bps Ba1 / BB+ 3.7 4.1 106.1 100 / 1 expensive potential withholding tax issues FR0011401736 ELECTRICITE DE FRANCE SA Perpetual 29.01.2020 4.250 7Y +302.1bps A3 / BBB+ 2.7 3.6 107.5 100 / 100 attractive XS1028600473 ORANGE SA Perpetual 07.02.2020 4.250 5Y + 307.9bps Baa3 / BBB- 3.4 3.6 103.9 100 / 1 attractive XS1050460739 TELEFONICA EUROPE BV Perpetual 31.03.2020 5.000 6Y +380.4bps Ba1 / BB+ 4.1 4.4 104.2 100 / 100 attractive XS0903531795 NGG FINANCE PLC 18.06.2076 18.06.2020 4.250 7Y +288bps Baa3 / BBB 2.8 3.7 107.7 100 / 1 expensive FR0012005924 ACCOR SA Perpetual 30.06.2020 4.125 5Y + 365.2bps N.A. / BB 4.0 4.1 100.6 100 / 100 fair DE000A11QR65 BAYER AG 01.07.2074 01.07.2020 3.000 0 Baa2 / BBB 2.5 2.7 102.8 1 / 1 expensive XS1048428012 VOLKSWAGEN INTL FIN NV Perpetual 24.03.2021 3.750 7Y + 278.4 Baa2 / BBB 2.8 3.2 105.7 1 / 1 fair XS1044811591 ENBW 02.04.2076 02.04.2021 3.625 5Y + 233.8bps Baa2 / BBB- 3.4 3.0 101.2 1 / 1 attr active FR0011531730 GDF SUEZ Perpetual 10.07.2021 4.750 5Y + 342.4bps A3 / BBB+ 2.9 3.9 111.3 100 / 100 fair XS0972588643 TELEFONICA EUROPE BV Perpetual 18.09.2021 7.625 8Y + 558.6bps Ba1 / BB+ 4.6 5.8 117.5 100 / 100 fair FR0011697010 ELECTRICITE DE FRANCE SA Perpetual 22.01.2022 4.125 8Y + 269.1bps A3 / BBB+ 3.1 3.3 106.6 100 / 100 attractive XS0943370543 DONG ENERGY A/S 26.06.3013 26.06.2023 6.250 5Y + 475bps Baa3 / BB+ 3.9 1.2 117.4 1 / 1 expensive XS0968913342 VOLKSWAGEN INTL FIN NV Perpetual 04.09.2023 5.125 10Y + 335bps Baa2 / BBB 3.3 4.1 113.8 1 / 1 fair XS1028599287 ORANGE SA Perp 07.02.2024 5.250 5Y + 366.8bps Baa3 / BBB- 4.2 4.2 107.6 100 / 1 fair XS1050461034 TELEFONICA EUROPE BV Perpetual 31.03.2024 5.875 10Y + 430.1bps Ba1 / BB+ 4.9 5.3 106.9 100 / 100 attractive FR0011942283 GDF SUEZ Perpetual 02.06.2024 3.875 10Y + 264.5bps A3 / BBB+ 3.3 2.0 104.3 100 / 100 expensive DE000A11QR73 BAYER AG 01.07.2073 01.07.2024 3.750 0 N.A. / BBB 3.1 2.9 105.2 1 / 1 expensive FR0011401751 ELECTRICITE DE FRANCE SA Perpetual 29.01.2025 5.375 12Y +379.4bps A3 / BBB+ 3.7 4.5 114.4 100 / 100 fair FR0011697028 ELECTRICITE DE FRANCE SA Perpetual 22.01.2026 5.000 5Y + 279.6bps A3 / BBB+ 3.8 4.2 110.7 100 / 100 fair XS1048428442 VOLKSWAGEN INTL FIN NV Perpetual 24.03.2026 4.625 12Y + 296.7bps Baa2 / BBB 3.7 4.0 108.4 1 / 1 expensive UBS CIO WM 19 September 2014 9

Appendix If you require information on UBS Chief Investment Office WM and its research products, please contact the mailbox ubs-ciowm@ubs.com (please note that e-mail communication is unsecured) or contact your client advisor for assistance. Disclosures (19 September 2014) Accor 4, 14, 21, 22; Alpiq Holding 6, 14, 21, 22; ArcelorMittal 4, 18, Bayer 9, 14, 21, 22; Casino 14, 21, 22; GDF Suez 14, General Electric Co. 3, 5, 9, 10, 12, 14, 16, 17, 18, 19, 20, 21, Henkel 14, Iberdrola 14, 21, 22; KPN Telecom 11, 14, 21, National Grid 14, 18, Orange 18, RWE 7, 14, 21, Siemens 1, 2, 14, 21, Telecom Italia 14, 15, 18, 21, Telefonica 8, 11, 13, 14, 18, 21, 22; Telefonica 8, 11, 13, 14, 18, 21, 22; Veolia Environnement 18, Volkswagen AG 2, 14, 1. UBS Deutschland AG is currently acting as advisor to Siemens AG 2. UBS Limited acts as broker to this company. 3. UBS Limited is acting as co-advisor to Banco Santander on its acquisition of General Electric's Nordic Banking Business 4. UBS AG, its affiliates or subsidiaries beneficially owned 1% or more of a class of this company's common equity securities as of last month's end (or the prior month's end if this report is dated less than 10 days after the most recent month's end). 5. A U.S.-based global equity strategist, a member of his team, or one of their household members has a long common stock position in General Electric. 6. UBS Limited is advising Alpiq Holding AG on the announced sale of its 35% stake in Swissgrid AG 7. The UBS Wealth Management strategist, a member of his or her team, or one of their household members has a long common stock position in this company. 8. UBS Limited is acting as advisor to Telefonica SA on the acquisition of 11.1% stake in Mediaset Premium 9. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and investment banking services are being, or have been, provided. 10. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and non-investment banking securities-related services are being, or have been, provided. 11. UBS Limited is advising Telefonica Deutschland on its acquisition of E-Plus from Koninklijke KPN NV. Telefonica Deutschland is a subsidiary of Telefonica SA 12. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and non-securities services are being, or have been, provided. 13. UBS Limited is acting as advisor to Telefonica SA on the acquisition of 56% of the share capital of Distribuidora de Television Digital S.A from Promotora de Informaciones S.A. and a further 22% in Distribuidora de Television Digital S.A from Mediaset Espana S.A. 14. UBS AG, its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from this company/entity within the next three months. 15. UBS Limited is acting as manager/co-manager, underwriter, placement or sales agent in regard to an offering of securities of this company/entity or one of its affiliates. 16. This company/entity is, or within the past 12 months has been, a client of UBS Financial Services Inc, and non-investment banking securities-related services are being, or have been, provided. 17. Within the past 12 months, UBS Financial Services Inc has received compensation for products and services other than investment banking services from this company. 18. UBS Securities LLC makes a market in the securities and/or ADRs of this company. 19. Within the past 12 months, UBS Securities LLC has received compensation for products and services other than investment banking services from this company/entity. 20. The equity analyst covering this company, a member of his or her team, or one of their household members has a long common stock position in this company. 21. Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking services from this company/entity. 22. UBS AG, its affiliates or subsidiaries has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months. UBS CIO WM 19 September 2014 10

Appendix Disclaimer UBS Chief Investment Office WM's investment views are prepared and published by Wealth Management and Retail & Corporate and Wealth Management Americas, Business Divisions of UBS AG (UBS, regulated by FINMA in Switzerland) or an affiliate thereof. In certain countries UBS AG is referred to as UBS SA. This material is for your information only and is not intended as an offer, or a solicitation of an offer, to buy or sell any investment or other specific product. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for sale to all investors. All information and opinions expressed in this material were obtained from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to its accuracy or completeness (other than disclosures relating to UBS, its subsidiaries and affiliates). All information and opinions as well as any prices indicated are current as of the date of this report, and are subject to change without notice. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. Opinions expressed herein may differ or be contrary to those expressed by other business areas or divisions of UBS, its subsidiaries and affiliates, as a result of using different assumptions and/or criteria. At any time UBS and other companies in the UBS group (or its employees) may have a long or short position, or deal as principal or agent, in relevant securities or provide advisory or other services to the issuer of relevant securities or to a company connected with an issuer. Some investments may not be readily realizable since the market in the securities is illiquid and therefore valuing the investment and identifying the risk to which you are exposed may be difficult to quantify. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, divisions or affiliates of UBS. Futures and options trading is considered risky. Past performance of an investment is no guarantee for its future performance. Additional information will be made available upon request. Some investments may be subject to sudden and large falls in value and on realization you may receive back less than you invested or may be required to pay more. Changes in foreign exchange rates may have an adverse effect on the price, value or income of an investment. The compensation of the analyst(s) who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of UBS Wealth Management & Swiss Bank as a whole, which includes investment banking, sales and trading services. We are of necessity unable to take into account the particular investment objectives, financial situation and needs of our individual clients and we would recommend that you take financial and/or tax advice as to the implications (including tax) of investing in any of the products mentioned herein. For structured financial instruments and funds the sales prospectus is legally binding. If you are interested you may attain a copy via UBS or a subsidiary of UBS. This material may not be reproduced or copies circulated without prior authority of UBS or a subsidiary of UBS. UBS expressly prohibits the distribution and transfer of this material to third parties for any reason. UBS will not be liable for any claims or lawsuits from any third parties arising from the use or distribution of this material. This report is for distribution only under such circumstances as may be permitted by applicable law. In developing the Chief Investment Office (CIO) economic forecasts, CIO economists worked in collaboration with economists employed by UBS Investment Research. Forecasts and estimates are current only as of the date of this publication and may change without notice. External Asset Managers / External Financial Consultants: In case this research or publication is provided to an External Asset Manager or an External Financial Consultant, UBS expressly prohibits that it is redistributed by the External Asset Manager or the External Financial Consultant and is made available to their clients and/or third parties.australia: 1) Clients of UBS Wealth Management Australia Ltd: This notice is distributed to clients of UBS Wealth Management Australia Ltd ABN 50 005 311 937 (Holder of Australian Financial Services Licence No. 231127), Chifley Tower, 2 Chifley Square, Sydney, New South Wales, NSW 2000, by UBS Wealth Management Australia Ltd.: This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such the content of the Document was prepared without taking into account the objectives, financial situation or needs of any specific recipient. Prior to making any investment decision, a recipient should obtain personal financial product advice from an independent adviser and consider any relevant offer documents (including any product disclosure statement) where the acquisition of financial products is being considered. 2) Clients of UBS AG: This notice is issued by UBS AG ABN 47 088 129 613 (Holder of Australian Financial Services Licence No 231087): This Document is issued and distributed by UBS AG. This is the case despite anything to the contrary in the Document. The Document is intended for use only by Wholesale Clients as defined in section 761G ( Wholesale Clients ) of the Corporations Act 2001 (Cth) ( Corporations Act ). In no circumstances may the Document be made available by UBS AG to a Retail Client as defined in section 761G of the Corporations Act. UBS AG s research services are only available to Wholesale Clients. The Document is general information only and does not take into account any person s investment objectives, financial and taxation situation or particular needs. Austria: This publication is not intended to constitute a public offer or a comparable solicitation under Austrian law and will only be used under circumstances which will not be equivalent to a public offering of securities in Austria. The document may only be used by the direct recipient of this information and may under no circumstances be passed on to any other investor. Bahamas: This publication is distributed to private clients of UBS (Bahamas) Ltd and is not intended for distribution to persons designated as a Bahamian citizen or resident under the Bahamas Exchange Control Regulations. Bahrain: UBS AG is a Swiss bank not licensed, supervised or regulated in Bahrain by the Central Bank of Bahrain and does not undertake banking or investment business activities in Bahrain. Therefore, Clients have no protection under local banking and investment services laws and regulations. Belgium: This publication is not intended to constitute a public offering or a comparable solicitation under Belgian law, but might be made available for information purposes to clients of UBS Belgium, branch of UBS (Luxembourg) SA, registered with the National Bank of Belgian and authorized by the Financial Services and Markets Authority", to which this publication has not been submitted for approval. Brazil: Prepared by UBS Brasil Administradora de Valores Mobiliários Ltda, entity regulated by Comissão de Valores Mobiliários ("CVM"). The views and opinions expressed in this report accurately reflect analyst's personal views about the subject securities and issuers. This report is only intended for Brazilian residents if such residents are directly purchasing or selling securities in the Brazil capital market through a local authorized institution. For investors residing in Brazil, Eligible Investors are considered to be: (i) financial institutions, (ii) insurance firms and investment capital companies, (iii) supplementary pension entities, (iv) entities that hold financial investments higher than R$ 300.000 and that confirm the status of qualified investors in written, (v) investment funds, (vi) securities portfolio managers and securities consultants duly authorized by CVM, regarding their own investments, and (vii) social security systems created by the Federal Government, States, and Municipalities. Canada: The information contained herein is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering, an offer to sell securities described herein, solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada or, alternatively, pursuant to a dealer registration exemption. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. Tax treatment depends on the individual circumstances and may be subject to change in the future. UBS does not provide legal or tax advice and makes no representations as to the tax treatment of assets or the investment returns thereon both in general or with reference to specific Client's circumstances and needs. Clients should obtain independent tax advice on the suitability of products, assets or instruments before investing and as they may consider appropriate. In Canada, this publication is distributed to clients of UBS Wealth Management Canada by UBS Investment Management Canada Inc. Dubai: Research is issued by UBS AG Dubai Branch within the DIFC, is intended for professional clients only and is not for onward distribution within the United Arab Emirates. France: This publication is distributed by UBS (France) S.A., French "société anonyme" with share capital of 125.726.944, 69, boulevard Haussmann F-75008 Paris, R.C.S. Paris B 421 255 670, to its clients and prospects. UBS (France) S.A. is a provider of investment services duly authorized according to the terms of the "Code Monétaire et Financier", regulated by French banking and financial authorities as the "Autorité de Contrôle Prudentiel et de Résolution." Egypt: Securities or other investment products are not being offered or sold by UBS to the public in Egypt and they have not been and will not be registered with the Egyptian Financial Supervisory Authority (EFSA). Germany: The issuer under German Law is UBS Deutschland AG, Bockenheimer Landstrasse 2-4, 60306 Frankfurt am Main. UBS Deutschland AG is authorized and regulated by the "Bundesanstalt für Finanzdienstleistungsaufsicht". Hong Kong: This publication is distributed to clients of UBS AG Hong Kong Branch by UBS AG Hong Kong Branch, a licensed bank under the Hong Kong Banking Ordinance and a registered institution under the Securities and Futures Ordinance. India: Distributed by UBS Securities India Private Ltd. 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment) INB010951437. Indonesia: This research or publication is not UBS CIO WM 19 September 2014 11

Appendix Disclaimer intended and not prepared for purposes of public offering of securities under the Indonesian Capital Market Law and its implementing regulations. Securities mentioned in this material have not been, and will not be, registered under the Indonesian Capital Market Law and regulations. Israel: UBS AG is registered as a Foreign Dealer in cooperation with UBS Wealth Management Israel Ltd, a wholly owned UBS subsidiary. UBS Wealth Management Israel Ltd is a licensed Portfolio Manager which engages also in Investment Marketing and is regulated by the Israel Securities Authority. This publication shall not replace any investment advice and/or investment marketing provided by a relevant licensee which is adjusted to your personal needs. This document may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been sent. Anyone who purchases the product[s] subject of this publication shall do so for its own benefit and for its own account and not with the aim or intention of distributing or offering the aforementioned product [s] to other parties. Anyone who purchases the product[s] shall do so in accordance with its own understanding and discretion and after it has received any relevant financial, legal, business, tax or other advice or opinion required by it in connection with such purchases. Italy: This publication is distributed to the clients of UBS (Italia) S.p.A., via del vecchio politecnico 3, Milano, an Italian bank duly authorized by Bank of Italy to the provision of financial services and supervised by "Consob" and Bank of Italy.UBS Italia has not participated in the production of the publication and of the research on investments and financial analysis herein contained. Jersey: UBS AG, Jersey Branch, is regulated and authorized by the Jersey Financial Services Commission for the conduct of banking, funds and investment business. Luxembourg: This publication is not intended to constitute a public offer under Luxembourg law, but might be made available for information purposes to clients of UBS (Luxembourg) S.A., a regulated bank under the supervision of the "Commission de Surveillance du Secteur Financier" (CSSF), to which this publication has not been submitted for approval. Mexico: This document has been distributed by UBS Asesores México, S.A. de C.V., a company which is not subject to supervision by the National Banking and Securities Commission of Mexico and is not part of UBS Grupo Financiero, S.A. de C.V. or of any other Mexican financial group and whose obligations are not guaranteed by any third party. UBS Asesores México, S.A. de C.V. does not guarantee any yield whatsoever.netherlands: This publication is not intended to constitute a public offering or a comparable solicitation under Dutch law, but might be made available for information purposes to clients of UBS Bank (Netherlands) B.V., a regulated bank under the supervision of De Nederlansche Bank" (DNB) and "Autoriteit Financiële Markten" (AFM), to which this publication has not been submitted for approval. Singapore: Please contact UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or report. Spain: This publication is distributed to clients of UBS Bank, S.A. by UBS Bank, S.A., a bank registered with the Bank of Spain. Taiwan: This document is distributed to qualified clients of UBS Securities Pte. Ltd., Taipei Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Taipei Branch. Thailand: At your specific request, this material has been provided to you. This document has not been approved by the Thai SEC, which has not verified the correctness or completeness of this document either on the issuing date of this document or later. This document has not passed any consideration by the Thai SEC. Investment in these securities involves risks investors should exercise due care and discretion in considering investment risk. The Investors should carefully study the investment risk and ensure that they have a good understanding of such risk. This is not an offer or sale to any person within Thailand. Turkey: No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey in the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board (the CMB) under the provisions of the Capital Market Law (Law No. 2499). Accordingly neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the CMB. However, according to article 15 (d) (ii) of the Decree No. 32 there is no restriction on the purchase or sale of the instruments by residents of the Republic of Turkey. UAE: This research report is not intended to constitute an offer, sale or delivery of shares or other securities under the laws of the United Arab Emirates (UAE). The contents of this report have not been and will not be approved by any authority in the United Arab Emirates including the UAE Central Bank or Dubai Financial Authorities, the Emirates Securities and Commodities Authority, the Dubai Financial Market, the Abu Dhabi Securities market or any other UAE exchange. UK: Approved by UBS AG, authorised and regulated by the Financial Market Supervisory Authority in Switzerland. In the United Kingdom, UBS AG is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. A member of the London Stock Exchange. This publication is distributed to private clients of UBS London in the UK. Where products or services are provided from outside the UK, they will not be covered by the UK regulatory regime or the Financial Services Compensation Scheme. USA: This document is not intended for distribution into the US and / or to US persons. UBS Securities LLC is a subsidiary of UBS AG and an affiliate of UBS Financial Services Inc., UBS Financial Services Inc. is a subsidiary of UBS AG. Version 03/2014. UBS 2014. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved. UBS CIO WM 19 September 2014 12